DOCSLIB.ORG

Overactive Cannabinoid 1 Receptor in Podocytes Drives Type 2 Diabetic Nephropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overactive Cannabinoid 1 Receptor in Podocytes Drives Type 2 Diabetic Nephropathy Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy Tony Jourdana,1, Gergo} Szandaa, Avi Z. Rosenbergb,c, Joseph Tama, Brian James Earleya, Grzegorz Godlewskia, Resat Cinara, Ziyi Liua, Jie Liua, Cynthia Jud, Pál Pachere, and George Kunosa,1 aLaboratory of Physiologic Studies, Section on Neuroendocrinology, and eSection on Oxidative Stress and Tissue Injury, Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, bKidney Diseases Section, National Institute on Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; cThe Johns Hopkins University School of Medicine, Baltimore, MD 21205; and dSkaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045 Edited by Lutz Birnbaumer, National Institute of Environmental Health Sciences, Research Triangle Park, NC, and approved October 30, 2014 (receivedfor review October 17, 2014) Diabetic nephropathy is a major cause of end-stage kidney disease, effective as globally acting ones in reversing obesity and its and overactivity of the endocannabinoid/cannabinoid 1 receptor metabolic sequelae (13, 14), and also delay the onset of overt (CB1R) system contributes to diabetes and its complications. Zucker T2DM (15) without inducing any behaviors that are predictive of diabetic fatty (ZDF) rats develop type 2 diabetic nephropathy with adverse neuropsychiatric effects in humans (13, 14). Conse- albuminuria, reduced glomerular filtration, activation of the renin- quently, there is considerable interest in translating these find- angiotensin system (RAS), oxidative/nitrative stress, podocyte loss, ings to clinical practice by developing peripherally restricted and increased CB1R expression in glomeruli. Peripheral CB1Rblock- CB1R antagonists/inverse agonists for clinical use. In this study ade initiated in the prediabetic stage prevented these changes or we used the Zucker diabetic fatty (ZDF) rat, a well-established reversed them when animals with fully developed diabetic ne- model of type 2 diabetic nephropathy (16, 17), to explore the phropathy were treated. Treatment of diabetic ZDF rats with los- role of peripheral CB1R in diabetic kidney disease, and the artan, an angiotensin II receptor-1 (Agtr1) antagonist, attenuated therapeutic potential of its inhibition by a nonbrain-penetrant the development of nephropathy and down-regulated renal corti- CB1R inverse agonist. We report that selective antagonism of cal CB1R expression, without affecting the marked hyperglycemia. peripheral CB1R can both prevent the deterioration of kidney In cultured human podocytes, CB1R and desmin gene expression function when treatment starts in the prediabetic stage and re- were increased and podocin and nephrin content were decreased verse it when treatment is started after the full development of ′ by either the CB1R agonist arachydonoyl-2 -chloroethylamide, an- diabetic nephropathy. The results also indicate that increased giotensin II, or high glucose, and the effects of all three were endocannabinoid/CB1R signaling in podocytes plays a key role in antagonized by CB1R blockade or siRNA-mediated knockdown of CNR1 the development of nephropathy, which can be dissociated from (the cannabinoid type 1 receptor gene). We conclude that in- the hyperglycemia and is likely induced via the RAS. creased CB1R signaling in podocytes contributes to the develop- ment of diabetic nephropathy and represents a common pathway Results through which both hyperglycemia and increased RAS activity ex- CB R Antagonism Prevents the Development of Nephropathy in ert their deleterious effects, highlighting the therapeutic potential 1 Prediabetic ZDF Rats. Six-week-old male, prediabetic ZDF rats of peripheral CB Rblockade. 1 were started on a daily oral dose (3 mg/kg) of the nonbrain penetrant CB R inverse agonist JD5037 or vehicle for 90 d. As endocannabinoid | podocyte | angiotensin II | nephropathy | 1 illustrated in Fig. 1A, vehicle-treated ZDF rats developed extreme hyperglycemia Significance iabetic nephropathy, a highly prevalent and serious com- Dplication of both type 1 and type 2 diabetes mellitus and a leading cause of renal failure, is characterized by albuminuria, Diabetic nephropathy is the leading cause of chronic kidney decreased glomerular filtration rate (GFR), mesangial expan- disease in the United States, and one of the most significant sion, thickening of the glomerular basement membrane, and long-term complications of both type 1 and type 2 diabetes, glomerular sclerosis (1). Multiple mechanisms have been impli- which currently lack fully effective therapy. Hyperglycemia and cated in the development of diabetic nephropathy, including activation of the renin-angiotensin system (RAS) are thought to activation of the renin-angiotensin system (RAS) (2), increase in be the two main drivers of this pathology. We have recently oxidative (3) and nitrosative/nitrative stress (4), as well as an shown that selective blockade of peripheral cannabinoid increase in local inflammation (5). receptor-1 (CB1R) delayed and attenuated the development of The endocannabinoid system plays a well-documented role in type 2 diabetes in a rat model. Here we show that the ne- obesity and its metabolic complications, including insulin re- phropathy-inducing effects of both hyperglycemia and activa- sistance and type 2 diabetes (T2DM). Globally acting cannabi- tion of the RAS involve CB1Ractivationinglomerularpodocytes, and that antagonism of peripheral CB1R could represent a novel, noid 1 receptor (CB1R) antagonists/inverse agonists improve obesity-related insulin resistance, dyslipidemia, fatty liver, and effective, and rational approach to both prevent and reverse β-cell loss, and attenuate obesity-related inflammatory changes diabetic nephropathy. both in preclinical models of diet-induced or genetic obesity and Author contributions: T.J., P.P., and G.K. designed research; T.J., G.S., J.T., B.J.E., G.G., R.C., in clinical trials in overweight subjects with metabolic syndrome Z.L., and J.L. performed research; C.J. contributed new reagents/analytic tools; T.J., A.Z.R., (reviewed in refs. 6 and 7). Global CB1R blockade also has and P.P. analyzed data; and T.J. and G.K. wrote the paper. beneficial effects in mouse models of type 1 and type 2 diabetic The authors declare no conflict of interest. – nephropathy (8 11). However, the therapeutic development of This article is a PNAS Direct Submission. this class of compounds has been halted because of adverse 1To whom correspondence may be addressed. Email: [email protected] or george. neuropsychiatric side effects in a small proportion of treated [email protected]. subjects (12). Recent studies in rodent models have demon- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. strated that peripherally restricted CB1R antagonists are as 1073/pnas.1419901111/-/DCSupplemental. E5420–E5428 | PNAS | Published online November 24, 2014 www.pnas.org/cgi/doi/10.1073/pnas.1419901111 Downloaded by guest on October 1, 2021 hyperglycemia by the end of the treatment period, accompanied by PNAS PLUS increased kidney weight, greatly elevated plasma creatinine and blood urea nitrogen levels, polydipsia, polyuria, a marked re- duction in GFR, as well as increased excretion of albumin, glucose, and uric acid, compared with lean controls. Chronic treatment of ZDF rats with JD5037 completely or nearly completely normalized all these parameters (Fig. 1A).Thesamedifferencewasevident for Cnr1 (the cannabinoid type 1 receptor gene) expression in the glomerulus, its diabetes-related increase being fully re- versed by treatment with JD5037 (Fig. 1B). Body weight gain was similar in vehicle-treated and JD5037-treated ZDF rats during the first 4 wk of treatment, as reported earlier (15), but as the vehicle-treated rats got sicker with extreme hyperglyce- mia, their body weight plateaued, whereas JD5037-treated rats continued to grow, resulting in significantly greater weight in the latter by the end of the treatment period (Fig. 1). CB1R immunoreactivity was also detectable in proximal tubular cells (Fig. S1), in agreement with earlier findings in the mouse (14), and the specificity of immunostaining was evident in its absence −/− in preparations from CB1R mice (Fig. S1). Vehicle-treated ZDF rats also displayed a marked reduction in the number of podocytes compared with control lean rats based on podocin and Wilms’ tumor (WT-1) immunostaining as well as podocalyxin/WT-1 double immunostaining, which was largely prevented by JD5037 treatment (Fig. 2A). CB1R protein was tightly colocalized with podocalyxin in the perisomal region of podocytes, indicating its expression primarily in podocytes (Fig. 2B). Consistent with podocyte loss, renal cortices of ZDF rats had much lower podocin mRNA (Nphs2) and protein (Fig. 2A) and lower nephrin (Nphs1) and zonula occludens-1 (Tjp1) mRNA, but higher desmin (Des) mRNA than cortices of control rats, and these changes were prevented by peripheral CB1R antagonism (Fig. 2C). Histopathological findings in glomeruli and tubulointerstitium of vehicle-treated ZDF rats were subtle and no vascular changes were noted. Occasional glomeruli contained podocytes with prominent MEDICAL SCIENCES protein resorption droplets (Fig. S2), although podocyte enlarge- ment was more commonly observed. No evidence of chronicity (glomerulosclerosis, interstitial fibrosis or tubular atrophy)
Load more

Recommended publications
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Mitochondrial ADP/ATP Exchange Inhibition
    www.nature.com/scientificreports OPEN Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying ibipinabant- Received: 27 March 2015 Accepted: 27 August 2015 induced myotoxicity Published: 29 September 2015 Tom J. J. Schirris1,2, Tina Ritschel3, G. Herma Renkema2,4, Peter H. G. M. Willems2,5, Jan A. M. Smeitink2,4 & Frans G. M. Russel1,2 Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Rimonabant, the first in class CB1R antagonist, was withdrawn from the market because of psychiatric side effects. This has led to the search for more peripherally restricted CB1R antagonists, one of which is ibipinabant. However, this 3,4-diarylpyrazoline derivative showed muscle toxicity in a pre-clinical dog study with mitochondrial dysfunction. Here, we studied the molecular mechanism by which ibipinabant induces mitochondrial toxicity. We observed a strong cytotoxic potency of ibipinabant in C2C12 myoblasts. Functional characterization of mitochondria revealed increased cellular reactive oxygen species generation and a decreased ATP production capacity, without effects on the catalytic activities of mitochondrial enzyme complexes I–V or the complex specific-driven oxygen consumption. Using in silico off-target prediction modelling, combined with in vitro validation in isolated mitochondria and mitoplasts, we identified adenine nucleotide translocase (ANT)-dependent mitochondrial ADP/ATP exchange as a novel molecular mechanism underlying ibipinabant-induced toxicity. Minor structural modification of ibipinabant could abolish ANT inhibition leading to a decreased cytotoxic potency, as observed with the ibipinabant derivative CB23. Our results will be instrumental in the development of new types of safer CB1R antagonists.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Endocannabinoids in Body Weight Control
    pharmaceuticals Review Endocannabinoids in Body Weight Control Henrike Horn †, Beatrice Böhme †, Laura Dietrich and Marco Koch * Institute of Anatomy, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany; [email protected] (H.H.); [email protected] (B.B.); [email protected] (L.D.) * Correspondence: [email protected]; Tel.: +49-341-97-22047 † These authors contributed equally. Received: 28 April 2018; Accepted: 28 May 2018; Published: 30 May 2018 Abstract: Maintenance of body weight is fundamental to maintain one’s health and to promote longevity. Nevertheless, it appears that the global obesity epidemic is still constantly increasing. Endocannabinoids (eCBs) are lipid messengers that are involved in overall body weight control by interfering with manifold central and peripheral regulatory circuits that orchestrate energy homeostasis. Initially, blocking of eCB signaling by first generation cannabinoid type 1 receptor (CB1) inverse agonists such as rimonabant revealed body weight-reducing effects in laboratory animals and men. Unfortunately, rimonabant also induced severe psychiatric side effects. At this point, it became clear that future cannabinoid research has to decipher more precisely the underlying central and peripheral mechanisms behind eCB-driven control of feeding behavior and whole body energy metabolism. Here, we will summarize the most recent advances in understanding how central eCBs interfere with circuits in the brain that control food intake and
    [Show full text]
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • Cannabinoid Receptor Cannabinoid Receptor
    Cannabinoid Receptor Cannabinoid Receptor Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol. www.MedChemExpress.com 1 Cannabinoid Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators (S)-MRI-1867 (±)-Ibipinabant Cat. No.: HY-141411A ((±)-SLV319; (±)-BMS-646256) Cat. No.: HY-14791A (S)-MRI-1867 is a peripherally restricted, orally (±)-Ibipinabant ((±)-SLV319) is the racemate of bioavailable dual cannabinoid CB1 receptor and SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent inducible NOS (iNOS) antagonist. (S)-MRI-1867 and selective cannabinoid-1 (CB-1) receptor ameliorates obesity-induced chronic kidney disease antagonist with an IC50 of 22 nM. (CKD). Purity: >98% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg 2-Arachidonoylglycerol 2-Palmitoylglycerol Cat. No.: HY-W011051 (2-Palm-Gl) Cat. No.: HY-W013788 2-Arachidonoylglycerol is a second endogenous 2-Palmitoylglycerol (2-Palm-Gl), an congener of cannabinoid ligand in the central nervous system. 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.
    [Show full text]
  • Phytocannabinoids Promote Viability and Functional Adipogenesis Of
    Biochemical Pharmacology 175 (2020) 113859 Contents lists available at ScienceDirect Biochemical Pharmacology journal homepage: www.elsevier.com/locate/biochempharm Phytocannabinoids promote viability and functional adipogenesis of bone T marrow-derived mesenchymal stem cells through different molecular targets Tariq Fellousa, Fabrizia De Maioa, Hilal Kalkana, Biagio Carannantea, Serena Boccellab, ⁎ ⁎ Stefania Petrosinoa, Sabatino Maioneb, Vincenzo Di Marzoa,c, , Fabio Arturo Iannottia, a Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli (NA) 80078 IT, Italy b Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy c Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Institut Universitaire de Cardiologie et de Pneumologie de Québec and Institut sur la Nutrition et les Aliments Fonctionnels, Université Laval, Quebec City G1V 0A6, Canada ARTICLE INFO ABSTRACT Keywords: The cellular microenvironment plays a critical role in the maintenance of bone marrow-derived mesenchymal Bone marrow-derived mesenchymal stem cells stem cells (BM-MSCs) and their subsequent cell lineage differentiation. Recent studies suggested that individuals (BM-MSCs) with adipocyte-related metabolic disorders have altered function and adipogenic potential of adipose stem cell Cannabidiol (CBD) subpopulations, primarily BM-MSCs, increasing the risk of heart attack, stroke
    [Show full text]
  • Novel CB1 Receptor Antagonist BAR-1 Modifies Pancreatic Islet Function
    Nava-Molina et al. Nutrition and Diabetes (2020) 10:7 https://doi.org/10.1038/s41387-020-0110-0 Nutrition & Diabetes ARTICLE Open Access Novel CB1 receptor antagonist BAR-1 modifies pancreatic islet function and clinical parameters in prediabetic and diabetic mice Lesly Nava-Molina1,ToyokazuUchida-Fuentes1, Héctor Ramos-Tovar1, Martha Fregoso-Padilla1, Marco Aurelio Rodríguez-Monroy1,AnaV.Vega 1, Gabriel Navarrete-Vázquez 2, Erik Andrade-Jorge1, Rafael Villalobos-Molina1, Ricardo Ortiz-Ortega1 and Alonso Vilches-Flores 1 Abstract Backgrouds: Cannabinoid receptor antagonists have been suggested as a novel treatment for obesity and diabetes. We have developed a synthetic cannabinoid receptor antagonist denominated BAR-1. As the function and integrity of a β-cell cellular structure are important keys for diabetes onset, we evaluated the effects of pharmacological administration of BAR-1 on prediabetic and diabetic rodents. Methods: CD-1 mice fed a hypercaloric diet or treated with streptozotocin were treated with 10 mg/kg BAR-1 for 2, 4 or 8 weeks. Body weight, oral glucose tolerance test, HbA1c, triglycerides and insulin in serum were measured. In isolated islets, we evaluated stimulated secretion and mRNA expression, and relative area of islets in fixed pancreases. Docking analysis of BAR-1 was complemented. Results: BAR-1 treatment slowed down weight gain in prediabetic mice. Fasting glucose–insulin relation also 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; decreased in BAR-1-treated mice and glucose-stimulated insulin secretion was increased in isolated islets, without effects in oral test. Diabetic mice treated with BAR-1 showed a reduced glucose and a partial recovery of islet integrity.
    [Show full text]
  • Are Cannabidiol and Δ9‐Tetrahydrocannabivarin Negative
    British Journal of DOI:10.1111/bph.12944 www.brjpharmacol.org BJP Pharmacology REVIEW Correspondence Dr John M McPartland, 53 Washington Street Ext., Middlebury, VT 05753, USA. Are cannabidiol and E-mail: [email protected] 9 ---------------------------------------------------------------- Δ Received -tetrahydrocannabivarin 21 February 2014 Revised 12 September 2014 negative modulators of the Accepted endocannabinoid system? A 16 September 2014 systematic review John M McPartland1, Marnie Duncan2, Vincenzo Di Marzo3 and Roger G Pertwee4 1Division of Molecular Biology, GW Pharmaceuticals, Salisbury, Wiltshire, UK, 2GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wiltshire, UK, 3Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, Napoli, Italy, and 4School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK Based upon evidence that the therapeutic properties of Cannabis preparations are not solely dependent upon the presence of Δ9-tetrahydrocannabinol (THC), pharmacological studies have been recently carried out with other plant cannabinoids (phytocannabinoids), particularly cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV). Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant. Here, we review in vitro and ex vivo mechanistic studies of CBD and THCV, and synthesize
    [Show full text]
  • Icrs2016 Programme
    PAGE | I TH 26 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY BUKOVINA POLAND JUNE 26 – JULY 1, 2016 TH 26 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY BUKOVINA POLAND JUNE 26 – JULY 1, 2016 Symposium Programming by Cortical Systematics LLC Copyright © 2016 International Cannabinoid Research Society Research Triangle Park, NC USA ISBN: 978-0-9892885-3-8 These abstracts may be cited in the scientific literature as follows: Author(s), Abstract Title (2016) 26th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 5R13DA016280 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. ICRS Sponsors Government Sponsors National Institute on Drug Abuse Non- Profit Organization Sponsors Kang Tsou Memorial Fund 2016 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D. President Michelle Glass, Ph.D. President- Elect Matt Hill, Ph.D. Past President Steve Alexander, Ph.D. Secretary Sachin Patel, M.D., Ph.D. Treasurer Steve Kinsey, Ph.D. International Secretary Roger Pertwee, M.a., D.Phil. , D.Sc. Student Representative Natalia Małek, M.Sc. Grant PI Jenny Wiley, Ph.D. Managing Director Jason Schechter, Ph.D. 2016 Symposium on the Cannabinoids Conference Coordinators Steve Alexander, Ph.D. Michelle Glass, Ph.D. Cecilia Hillard, Ph.D.
    [Show full text]
  • The Toxicological Evaluation of Rimonabant
    FABAD J. Pharm. Sci., 33, 95–108, 2008 SCIENTIFIC REVIEW The Toxicological Evaluation of Rimonabant, Taranabant, Surinabant and Otenabant In The Treatment of Obesity: Why The Trials On Endocannabinoid Receptor Antagonists and Inverse Agonists Are Suspended? Pınar ERKEKOĞLU*, Belma GİRAY*, Gönül ŞAHİN*° The Toxicological Evaluation of Rimonabant, Taranabant Obezite Tedavisinde Kullanılan Rimonabant, Surinabant and Otenabant in the Treatment of Obesity: Taranabant Surinabant ve Otenabant’ın Toksikolojik Why the Trials on Endocannabinoid Receptor Antagonists Açıdan Değerlendirilmesi: Endocannabinoid Reseptör and Inverse Agonists are Suspended? Antagonistleri ve Ters Agonistler Üzerindeki Denemeler Neden Durduruldu? Summary Özet Obesity is a condition in which excess body fat has accu- Obezite, vücut yağının sağlık üzerine olumsuz etkiler mulated to the high extent that may have adverse effects on yaratabilecek şekilde yüksek miktarda birikmesidir. Hayat health. Obesity may lead to reduced life quality and expect- kalitesinin ve beklentisinin azalmasına yol açabilir. Ayrıca, ancy. Besides, it may cause serious health problems. Several ciddi sağlık problemlerine neden olabilir Birçok anorektik anorectic anti-obesitic drugs have been developed with quite anti-obezitik ilaç geliştirilmiş, bunların çok azı klinik a few entering clinical trials. Currently, there are only two çalışmalara girebilmiştir. Obezite tedavisinde kullanılan iki drugs (sibutramine and orlistat) commercially available. ilacın (sibutramin ve orlistat) satışı hali hazırda mevcuttur. Drugs acting on endocannabinoid system (EC) were expected Endokannabinoid sistem (EC) üzerine etki eden ilaçların da to be successful on preventing weight gain. Rimonabant was kilo alımını önlemede başarılı olabilecekleri düşünülmüştür. the first to be on market in 2006. However, the drug’s ap- Rimonabant, 2006’da satışa sunulan ilk ürün olmuştur. proval has been withdrawn in 2008 due to its adverse effects, Ancak, özellikle psikiyatrik bozukluklar başta olmak especially of its potential to cause psychiatric disorders.
    [Show full text]
  • Biomolecules 2019 Mollica.Pdf
    biomolecules Article Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity Marilisa P. Dimmito 1, Azzurra Stefanucci 1,*, Stefano Pieretti 2 , Paola Minosi 2, Szabolcs Dvorácskó 3, Csaba Tömböly 3, Gokhan Zengin 4 and Adriano Mollica 1 1 Department of Pharmacy, University of Chieti-Pescara “G. d’Annunzio”, Via dei Vestini 31, 66100 Chieti, Italy; [email protected] (M.P.D.); [email protected] (A.M.) 2 Istituto Superiore di Sanità, Centro Nazionale Ricerca e Valutazione Preclinica e Clinica dei Farmaci, Viale Regina Elena 299, 00161 Rome, Italy; [email protected] (S.P.); [email protected] (P.M.) 3 Institute of Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences, Temesvári krt. 62, 6726 Szeged, Hungary; [email protected] (S.D.); [email protected] (C.T.) 4 Department of Biology, Science Faculty, Selcuk University, 42005 Konya, Turkey; [email protected] * Correspondence: [email protected]; Tel.: +39-0871-3554-482 Received: 7 August 2019; Accepted: 11 September 2019; Published: 16 September 2019 Abstract: The endocannabinoid system represents an integrated neuronal network involved in the control of several organisms’ functions, such as feeding behavior. A series of hybrids of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (mimonabant), a well-known inverse agonist of the type-1 cannabinoid receptor (CB1), once used as an antiobesity drug, and the N-(2S)-substitutes of 1-[(4-fluorophenyl)methyl]indazole-3-carboxamide with 1-amino-3-methyl-1-oxobutane (AB-Fubinaca), 1-amino-3,3-dimethyl-1-oxobutane (ADB-Fubinaca), and 3-methylbutanoate (AMB-Fubinaca), endowed with potent agonistic activity towards cannabinoid receptors CB1 and CB2 were in solution as C-terminal amides, acids, methyl esters and N-methyl amides.
    [Show full text]